DDC

Texas Medical Center Digestive Diseases Center

WEEKLY GI RESEARCH WEBINAR

"Direct targeting of STAT3 to reverse fibrosis"

Uddalak Bharadwaj, Ph.D.

Assistant Professor

Infectious Diseases

MD Anderson Cancer Center

Be informed about a highly-potent, non-toxic, direct STAT3 inhibitor, TTI-101, with excellent bio-availability, currently in a Phase I clinical trial (7 different cancers, including HCC, https://clinicaltrials.gov/ct2/show/NCT03195699. Know about its inhibitory effect on inflammation and fibrosis, especially, as it pertains to Hepatocellular Carcinoma

Jung KH, Yoo W, Stevenson HL, et al. Multi-functional effects of a small-molecule STAT3 inhibitor on NASH and HCC in mice. Clin Cancer Res. 2017 May 22. PMID: 28533225 DOI: 10.1158/1078-0432.CCR-16-2253

Bharadwaj U, Eckols TK, Xu X, et al. Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma. Oncotarget. 2016 May 3;7(18):26307-30. doi: 10.18632/oncotarget.8368. PubMed PMID: 27027445

Bharadwaj U, Kasembeli MM, Robinson P, et al. Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution. Pharmacol Rev. 2020 Apr;72(2):486-526. doi: 10.1124/pr.119.018440

SEPT 17 • 4:00 PM

REGISTER AT

HTTPS://EVENT.WEBINARJAM.COM/CHANNEL/DDCRESEARCHFORUM